Denali Therapeutics Dirección
Dirección controles de criterios 4/4
El CEO de Denali Therapeutics' es Ryan Watts , nombrado en Aug 2015, tiene una permanencia de 8.67 años. compensación anual total es $7.88M, compuesta por 8.5% salario y 91.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.57% de las acciones de la empresa, por valor de $34.83M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 7.5 años, respectivamente.
Información clave
Ryan Watts
Chief Executive Officer (CEO)
US$7.9m
Compensación total
| Porcentaje del salario del CEO | 8.5% |
| Permanencia del CEO | 8.8yrs |
| Participación del CEO | 1.6% |
| Permanencia media de la dirección | 5.4yrs |
| Promedio de permanencia en la Junta Directiva | 7.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Just Slashed This Year's Estimates
Mar 07Denali Therapeutics: 2021 Was Mostly Bad Luck And Trouble
Feb 25Are Investors Undervaluing Denali Therapeutics Inc. (NASDAQ:DNLI) By 28%?
Feb 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
| Sep 30 2019 | n/a | n/a | -US$66m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$52m |
| Dec 31 2018 | US$6m | US$545k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$137m |
| Jun 30 2018 | n/a | n/a | -US$123m |
| Mar 31 2018 | n/a | n/a | -US$91m |
| Dec 31 2017 | US$1m | US$481k | -US$88m |
Compensación vs. Mercado: La compensación total ($USD7.88M) de Ryan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.66M).
Compensación vs. Ingresos: La compensación de Ryan ha sido consistente con los resultados de la empresa en el último año.
CEO
Ryan Watts (48 yo)
8.8yrs
Permanencia
US$7,879,267
Compensación
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 8.8yrs | US$7.88m | 1.57% $ 48.4m | |
| Co-Founder | 9.3yrs | US$4.17m | 0.41% $ 12.6m | |
| Co-Founder & Independent Director | no data | US$431.93k | 1.48% $ 45.6m | |
| Chief Medical Officer & Head of Development | 9yrs | US$4.17m | 0.16% $ 4.8m | |
| Senior Vice President of Corporate Finance | no data | sin datos | sin datos | |
| Chief Technical and Manufacturing Officer | 5.8yrs | sin datos | sin datos | |
| Chief Scientific Officer | 3.9yrs | sin datos | sin datos | |
| Vice President of Investor Relations | 4.4yrs | sin datos | sin datos | |
| General Counsel | 5.4yrs | sin datos | sin datos | |
| Vice President of Corporate Development | 1.4yrs | sin datos | sin datos | |
| Chief People Officer | no data | sin datos | sin datos | |
| Chief Commercial Officer | 2.8yrs | sin datos | sin datos |
5.4yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DNLI es experimentado (5.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$7.88m | 1.57% $ 48.4m | |
| Co-Founder & Independent Director | 9.3yrs | US$431.93k | 1.48% $ 45.6m | |
| Independent Chairperson | 9.2yrs | US$459.43k | 0.082% $ 2.5m | |
| Independent Director | 9.2yrs | US$444.43k | 0.24% $ 7.4m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 9.2yrs | US$439.43k | 0.051% $ 1.6m | |
| Member of Scientific Advisory Board | 3.6yrs | sin datos | sin datos | |
| Independent Director | 6.3yrs | US$439.43k | 0.011% $ 335.5k | |
| Independent Director | 5.6yrs | US$429.43k | 0.0099% $ 304.0k | |
| Director | 2.1yrs | US$419.43k | 0.62% $ 19.1m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 3.4yrs | sin datos | sin datos |
7.7yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de DNLI se considera experimentada (7.5 años de antigüedad promedio).